Neutrophil to lymphocyte ratio and C-reactive protein level as a prognostic marker in mild versus severe COVID-19 patients
Gastroenterology and Hepatology from Bed to Bench,
20 September 2020
Aim: This research aims to investigate neutrophil‐to‐lymphocyte ratio (NLR) with C‐reactive protein to identify potential clinical predictors and to analyze differences among severe and non-severe COVID-19 patients.
Background: NLR and CRP are established inflammation markers that reflect systemic inflammatory. The patients with novel coronavirus (SARS-CoV-2) infected pneumonia (COVID-19), indicating severe patients tended to have higher NLR.
Methods: A population of patients with COVID-19 referred to Loghman hospital, in Tehran was analyzed. The baseline data of laboratory examinations, including NLR and CRP levels were collected. The Pearson analysis was developed to assess the independent relationship between the NLR with disease severity and CRP levels.
Results: COVID-19 cases include 14 (20%) of patients with severity disease and 56 (80%) with non-severe COVID-19 disease. The mean number of WBC, NEU, LYM and NLR of severe patients were significantly higher than those of non-severe patients. 46 (65.7%) of patients had NLR >1 and the remaining patients were NLR <1. The plasma CRP levels in severe cases were higher than non-severe cases that this difference was significant. The results showed that NLR was positively correlated with CRP levels (R=0.23) and negatively correlated with WBC (R=-0.38).The CRP (AUC = 0.97, 95% CI: 0.95-0.99), NLR (AUC = 0.87, 95% CI: 0.81-0.93), had very good accuracy in predicting disease severity of COVID-19 disease.
Conclusion: We concluded the NLR and CRP are an independent risk factor for disease severity of COVID-19 patients in respect to further researches are needed to confirm our findings.
- Neutrophil‐to‐lymphocyte ratio (NLR), CRP, COVID-19, severity of COVID-19, SARS-CoV-2
2. Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. International journal of biological sciences. 2020;16(10):1678.
3. of the International CSG. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology. 2020;5(4):536.
4. Zhang DX. SARS-CoV-2: air/aerosols and surfaces in laboratory and clinical settings. The Journal of Hospital Infection. 2020.
5. Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiology Australia. 2020;41(1):45-50.
6. Polak SB, Van Gool IC, Cohen D, Jan H, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathology. 2020:1-11.
7. Yi Y, Lagniton PN, Ye S, Li E, Xu R-H. COVID-19: what has been learned and to be learned about the novel coronavirus disease. International journal of biological sciences. 2020;16(10):1753.
8. Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, et al. Therapeutic strategies for critically ill patients with COVID-19. Annals of Intensive Care. 2020;10:1-9.
9. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang Y-Q, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal transduction and targeted therapy. 2020;5(1):1-3.
10. Zheng Y, Huang Z, Ying G, Zhang X, Ye W, Hu Z, et al. Comparative study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting uncontrolled inflammation might not be the main reason of tissue injury. medRxiv. 2020.
11. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID‐19. American journal of hematology. 2020.
12. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al., editors. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. Open Forum Infectious Diseases; 2020: Oxford University Press US.
13. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with COVID-19. medRxiv. 2020.
14. Yan L, Zhang H-T, Goncalves J, Xiao Y, Wang M, Guo Y, et al. An interpretable mortality prediction model for COVID-19 patients. Nature Machine Intelligence. 2020:1-6.
15. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases. 2020.
16. Meng L-B, Yu Z-M, Guo P, Wang Q-Q, Qi R-M, Shan M-J, et al. Neutrophils and neutrophil-lymphocyte ratio: Inflammatory markers associated with intimal-media thickness of atherosclerosis. Thrombosis Research. 2018;170:45-52.
17. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. 2020.
18. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clinical Infectious Diseases. 2020.
19. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. Journal of Infection. 2020.
20. Mardani R, Vasmehjani AA, Zali F, Gholami A, Nasab SDM, Kaghazian H, et al. Laboratory parameters in detection of COVID-19 patients with positive RT-PCR; a diagnostic accuracy study. Archives of Academic Emergency Medicine. 2020;8(1).
21. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases. 2020.
22. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investigative radiology. 2020.
23. Lagunas‐Rangel FA. Neutrophil‐to‐lymphocyte ratio and lymphocyte‐to‐C‐reactive protein ratio in patients with severe coronavirus disease 2019 (COVID‐19): A meta‐analysis. Journal of medical virology. 2020.
24. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel medicine and infectious disease. 2019;29:48-50.
25. Leist SR, Jensen KL, Baric RS, Sheahan TP. Increasing the translation of mouse models of MERS coronavirus pathogenesis through kinetic hematological analysis. PloS one. 2019;14(7):e0220126.
26. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. Journal of medical virology. 2020.
27. Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine. 2020;18:1-12.
28. Russell CD, Parajuli A, Gale HJ, Bulteel NS, Schuetz P, de Jager CP, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis. Journal of Infection. 2019;78(5):339-48.
29. Han Q, Wen X, Wang L, Han X, Shen Y, Cao J, et al. Role of hematological parameters in the diagnosis of influenza virus infection in patients with respiratory tract infection symptoms. Journal of clinical laboratory analysis. 2020;34(5):e23191.
- Abstract Viewed: 0 times